成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Protein Tyrosine Kinase/RTK Autophagy
  3. Bcr-Abl Autophagy
  4. Nilotinib

Nilotinib  (Synonyms: 尼洛替尼; AMN107)

目錄號(hào): HY-10159 純度: 99.94%
COA 產(chǎn)品使用指南

Nilotinib是一種口服可用的具有抗腫瘤活性的 Bcr-Abl 酪氨酸激酶抑制劑。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

我們將采用定制合成服務(wù)的方式為您快速提供所需產(chǎn)品和技術(shù)服務(wù)

Nilotinib Chemical Structure

Nilotinib Chemical Structure

CAS No. : 641571-10-0

1.  客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥385
In-stock
25 mg ￥350
In-stock
50 mg ￥550
In-stock
100 mg ￥850
In-stock
200 mg ￥1234
In-stock
500 mg ￥2413
In-stock
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Nilotinib:

MCE 顧客使用本產(chǎn)品發(fā)表的 33 篇科研文獻(xiàn)

Proliferation Assay
IHC

    Nilotinib purchased from MCE. Usage Cited in: Oncotarget. 2018 Apr 24;9(31):22158-22183.  [Abstract]

    Primary tumors are dissected at the end of experiment and subjected to immunohistochemistry. Representative images of primary tumor sections stained with anti-PCNA (proliferation), anti-cleaved caspase 3 (apoptosis), and anti-CD31 (angiogenesis).

    Nilotinib purchased from MCE. Usage Cited in: Leuk Lymphoma. 2015;56(8):2416-23.  [Abstract]

    Cell cycle analysis of HT93A cells by flow cytometry. Cells are treated with 100 nM Nilotinib and 50 ng/mL G-CSF alone or in combination for 48 h before the cell cycle is analyzed. Nilotinib treatment increases the fraction of cells in G0/G1 phase and decreased the S+G2/M-phase fraction.

    • 生物活性

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.

    IC50 & Target

    Bcr-Abl[1]
    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    6.63 μM
    Compound: 2
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    BaF3 IC50
    > 1 μM
    Compound: 1
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    		[PMID: 26195136]
    BaF3 GI50
    > 10 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-T315I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    > 100 nM
    Compound: Nilotinib
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    Cytotoxicity against mouse BAF3 cells expressing BCR-ABL T315I mutant assessed as inhibition of cell growth measured after 48 hrs by trypan blue assay
    		[PMID: 34011155]
    BaF3 IC50
    0.003 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL M351T mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    0.004 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    0.0095 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F486S mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    0.017 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-M351T mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.021 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-E255K mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    0.022 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing wild type BCR-ABL assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    0.023 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Q252H mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.025 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-H369P mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.0546 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317I mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    0.12 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E359V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.12 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Q252H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.13 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E355G mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.15 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL G250E mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.16 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317L mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    0.17 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255K mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    0.202 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-F317L mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.47 μM
    Compound: Nilotinib
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-SRC (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    0.87 μM
    Compound: Nilotinib
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-LCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    1 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253H mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    1.093 μM
    Compound: Nilotinib
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of BCR/ABL p210-Y253F mutant (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 GI50
    1.1 μM
    Compound: Nilotinib
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR1 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    1.2 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL E255V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    1.3 μM
    Compound: Nilotinib
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-BLK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    1.4 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL Y253F mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    1.4 μM
    Compound: Nilotinib
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-DDR2 (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    1.54 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M244V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    10.3 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl M351T mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    11.8 nM
    Compound: Nilotinib
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against mouse BAF3 cells expressing native BCR-ABL assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    BaF3 IC50
    15.1 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    150 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Q252H mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    159 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F359V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    16 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 GI50
    2.1 μM
    Compound: Nilotinib
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    2.7 μM
    Compound: Nilotinib
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL T315I mutant after 72 hrs by MTT assay
    		[PMID: 26814890]
    BaF3 IC50
    2.9 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL F317V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    21 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl F486S mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    21.1 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL H396R mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    292 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255K mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    3 μM
    Compound: 2
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    Cytotoxicity against mouse BA/F3 cells expressing BCR-ABL L248V mutant assessed as growth inhibition after 72 hrs by CCK-8 assay
    		[PMID: 23301703]
    BaF3 IC50
    314 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253H mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    38.6 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl G250E mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 GI50
    4.1 μM
    Compound: Nilotinib
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    Inhibition of TEL-HCK (unknown origin) expressed in mouse BA/F3 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    BaF3 IC50
    40750 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    473 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E255V mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    6.34 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396P mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    60.7 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl Y253F mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    65.2 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    775 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl T315I mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    8.38 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl E355G mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BaF3 IC50
    87.2 nM
    Compound: 2, AMN107
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    Antiproliferative activity against mouse BA/F3 cells expressing Bcr-Abl H396R mutant after 72 hrs by CCK-8 assay
    		[PMID: 23088644]
    BJ IC50
    12.8 μM
    Compound: Tasigna
    Antiproliferative activity against human BJ cells after 72 hrs by PrestoBlue colorimetric assay
    Antiproliferative activity against human BJ cells after 72 hrs by PrestoBlue colorimetric assay
    		[PMID: 24835982]
    CHO IC50
    4.7 μM
    Compound: nilotinib
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    		[PMID: 23812503]
    Daoy IC50
    6 μM
    Compound: Nilotinib
    Antiproliferative activity against human Daoy cells assessed as inhibition of cell growth incubated for 72 hrs by Alamar blue dye based fluorescence spectrophotometric assay
    Antiproliferative activity against human Daoy cells assessed as inhibition of cell growth incubated for 72 hrs by Alamar blue dye based fluorescence spectrophotometric assay
    		[PMID: 33636537]
    H9c2 IC50
    21.33 μM
    Compound: Nilotinib
    Cytotoxicity against rat H9c2 cells incubated for 48 hrs and measured by MTT assay
    Cytotoxicity against rat H9c2 cells incubated for 48 hrs and measured by MTT assay
    		[PMID: 36283251]
    HCT-116 IC50
    2.39 μM
    Compound: 2
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    HCT-116 IC50
    5.75 μM
    Compound: Nilotinib
    Antiproliferative activity against human HCT-116 cells overexpressing DDR1 assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human HCT-116 cells overexpressing DDR1 assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33246255]
    HEK293 IC50
    0.5 μM
    Compound: nilotinib
    Inhibition of the Organic Cation Transporter 3 (OCT3, SLC22A3) as assessed by a phenotypic impedance-based assay detecting changes in cell morphology by MPP+ uptake in HEK-293 JumpIN-SLC22A3 cells
    Inhibition of the Organic Cation Transporter 3 (OCT3, SLC22A3) as assessed by a phenotypic impedance-based assay detecting changes in cell morphology by MPP+ uptake in HEK-293 JumpIN-SLC22A3 cells
    		[PMID: 35163125]
    HEK293 IC50
    3.7 nM
    Compound: Tasigna, AMN107
    Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of DDR1 expressed in HEK293 cells by ELISA
    		[PMID: 20817538]
    HEK293 IC50
    5.2 nM
    Compound: Tasigna, AMN107
    Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of DDR2 expressed in HEK293 cells by ELISA
    		[PMID: 20817538]
    HEK293 IC50
    677 nM
    Compound: Tasigna, AMN107
    Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA
    Inhibition of autophosphorylation of CSF1R expressed in HEK293 cells by ELISA
    		[PMID: 20817538]
    HEK293 IC50
    8.3 μM
    Compound: AMN107
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay
    Cytotoxicity against HEK293 cells assessed as reduction in cell viability measured after 48 hrs by alamar blue assay
    		[PMID: 35944901]
    HEK293 IC50
    8.4 μM
    Compound: Nilotinib
    Cytotoxicity against HEK293 cells incubated for 48 hrs and measured by MTT assay
    Cytotoxicity against HEK293 cells incubated for 48 hrs and measured by MTT assay
    		[PMID: 36283251]
    HEL GI50
    3.9 μM
    Compound: Nilotinib
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human HEL cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    Jurkat IC50
    > 1000 nM
    Compound: Nilotinib
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    K562 IC50
    < 100 nM
    Compound: Nilotinib
    Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to DDR1 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    		[PMID: 28280261]
    K562 GI50
    > 1000 nM
    Compound: AMN107
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells expressing BCR-ABL T315I mutant measured after 48 hrs by alamarblue assay
    		[PMID: 35944901]
    K562 GI50
    0.002 μM
    Compound: Nilotinib
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human K562 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    K562 IC50
    0.0039 μM
    Compound: Nilotinib
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 26814890]
    K562 IC50
    0.015 μM
    Compound: 2
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    		[PMID: 23521020]
    K562 IC50
    0.022 μM
    Compound: 1
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    Antiproliferative activity against human K562 cells expressing wild type Bcr-Abl after 72 hrs by CCK-8 assay
    		[PMID: 26195136]
    K562 IC50
    1.8 nM
    Compound: Nilotinib
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    K562 IC50
    1.8 μM
    Compound: Nilotinib
    Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to NQO2 in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    		[PMID: 28280261]
    K562 IC50
    2.4 μM
    Compound: Tasigna
    Antiproliferative activity against apoptosis-resistant, Philadelphia chromosome-positive human K562 cells after 72 hrs by PrestoBlue colorimetric assay
    Antiproliferative activity against apoptosis-resistant, Philadelphia chromosome-positive human K562 cells after 72 hrs by PrestoBlue colorimetric assay
    		[PMID: 24835982]
    K562 GI50
    26 nM
    Compound: AMN107
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    Growth inhibition of human K562 cells measured after 48 hrs by alamarblue assay
    		[PMID: 35944901]
    K562 IC50
    28 nM
    Compound: Nilotinib
    Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    Inhibition of kinobead binding to ABL in human K562 cells incubated for 30 mins by iTRAQ reagent-based mass spectrometric method
    		[PMID: 28280261]
    K562 IC50
    89.13 μM
    Compound: Nilotinib
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 23538233]
    KBM5 IC50
    12 nM
    Compound: NLT
    Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human KBM5 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31727471]
    KBM5 IC50
    2421 nM
    Compound: NLT
    Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human KBM5 cells expressing IM-resistant Bcr/Abl T315I mutant assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31727471]
    KU812 cell line GI50
    0.001 μM
    Compound: Nilotinib
    Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human KU812 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    KU812 cell line IC50
    1.8 nM
    Compound: Nilotinib
    Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human KU812 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    KU812 cell line IC50
    10 nM
    Compound: NLT
    Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human KU812 cells expressing IM- sensitive wild type Bcr/Abl assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31727471]
    L02 IC50
    40.39 μM
    Compound: Nilotinib
    Cytotoxicity against human L02 cells incubated for 48 hrs and measured by MTT assay
    Cytotoxicity against human L02 cells incubated for 48 hrs and measured by MTT assay
    		[PMID: 36283251]
    MCF7 IC50
    6.92 μM
    Compound: 2
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    MDA-MB-231 IC50
    7.31 μM
    Compound: Nilotinib
    Antiproliferative activity against human MDA-MB-231 cells overexpressing DDR1 assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells overexpressing DDR1 assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
    		[PMID: 33246255]
    MDA-MB-435S IC50
    2.66 μM
    Compound: 2
    Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-435S cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    MEG-01 GI50
    0.016 μM
    Compound: Nilotinib
    Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MEG01 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    MOLM-14 GI50
    > 10 μM
    Compound: Nilotinib
    Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MOLM14 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    MV4-11 GI50
    > 10 μM
    Compound: Nilotinib
    Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    NCI-H2286 IC50
    1.8 μM
    Compound: Nilotinib
    Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay
    Antiproliferative activity against human NCI-H2286 cells expressing DDR2 mutant after 72 hrs by alamar blue assay
    		[PMID: 26191369]
    NCI-H23 IC50
    3.05 μM
    Compound: 2
    Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H23 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    NCI-H460 IC50
    14.41 μM
    Compound: 2
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    Sf21 IC50
    0.158 μM
    Compound: Nilotinib
    Inhibition of recombinant human N-terminal GST-tagged c-Kit (544 to end residues) expressed in baculovirus infected Sf21 insect cells using FAM-labelled P22 peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1
    Inhibition of recombinant human N-terminal GST-tagged c-Kit (544 to end residues) expressed in baculovirus infected Sf21 insect cells using FAM-labelled P22 peptide as substrate preincubated for 10 mins followed by substrate addition and measured after 1
    		[PMID: 32051094]
    SH-SY5Y IC50
    38.51 μM
    Compound: Nilotinib
    Cytotoxicity against human SH-SY5Y cells incubated for 48 hrs and measured by MTT assay
    Cytotoxicity against human SH-SY5Y cells incubated for 48 hrs and measured by MTT assay
    		[PMID: 36283251]
    T47D IC50
    6.08 μM
    Compound: 2
    Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
    Antiproliferative activity against human T47D cells after 72 hrs by MTT assay
    		[PMID: 23521020]
    THP-1 IC50
    400 nM
    Compound: Nilotinib
    Antiinflammatory activity against LPS-stimulated human THP-1 cells assessed as TNF-alpha secretion pretreated for 1 hr followed by LPS stimulation and measured upto 24 hrs by ELISA analysis
    Antiinflammatory activity against LPS-stimulated human THP-1 cells assessed as TNF-alpha secretion pretreated for 1 hr followed by LPS stimulation and measured upto 24 hrs by ELISA analysis
    		[PMID: 36094045]
    U-937 GI50
    > 10 μM
    Compound: Nilotinib
    Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    Antiproliferative activity against human U937 cells assessed as cell viability after 72 hrs by CellTiter-Glo or CCK-8 assay
    		[PMID: 26789553]
    U-937 IC50
    > 1000 nM
    Compound: Nilotinib
    Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    Cytotoxicity against human U-937 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
    		[PMID: 34011155]
    體外研究
    (In Vitro)

    Nilotinib (AMN107) 是一種選擇性 Abl 抑制劑，旨在與 BCR-ABL 的 ATP 結(jié)合位點(diǎn)相互作用，其親和力比 imatinib (HY-15463) 更高，同時(shí)與 imatinib 相比效力明顯更強(qiáng) (IC50<30 nM)，并且對(duì)大多數(shù)導(dǎo)致 imatinib 耐藥的 BCR-ABL 點(diǎn)突變體保持活性[1]。
    Nilotinib 對(duì) GIST 異種移植瘤系和 imatinib 耐藥 GIST 細(xì)胞系表現(xiàn)出明顯的抗腫瘤作用，其中親本細(xì)胞系 GK1C 和 GK3C 對(duì) imatinib 敏感，IC50分別為4.59 μM和11.15 μM，imatinib 耐藥細(xì)胞系 GK1C-IR 和 GK3C-IR 對(duì) imatinib 耐藥，IC50值分別為 11.74 (P<0.001) 和 41.37 (P<0.001)[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    Nilotinib (口服灌胃; 40 mg/kg; 一天一次，連續(xù)4周) 在患有 GIST 異種移植的 BALB/cSLc-nu/nu 小鼠中表現(xiàn)出相同或更高的抗腫瘤作用[2]。
    Nilotinib 對(duì) Indomethacin 誘導(dǎo)的大鼠腸炎模型的宏觀和微觀病理評(píng)分具有顯著的改善作用，并能確保腸道黏膜的顯著愈合，同時(shí)降低結(jié)腸中 PDGFR α 和 β 水平及細(xì)胞凋亡評(píng)分[3]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: BALB/cSLc-nu/nu mice with GIST xenograft (GK1X, GK2X and GK3X)[2]
    Dosage: 40 mg/kg
    Administration: Oral gavage; daily; 4 weeks
    Result: Inhibited tumor growth by 69.6% in GK1X, 85.3% in GK2X and 47.5% in GK3X xenograft line.
    Clinical Trial
    分子量

    529.52

    Formula

    C28H22F3N7O
    CAS 號(hào)
    性狀

    固體

    顏色

    White to light yellow

    中文名稱

    尼洛替尼；尼羅替尼
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 12.5 mg/mL (23.61 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 1.8885 mL 9.4425 mL 18.8850 mL
    5 mM 0.3777 mL 1.8885 mL 3.7770 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 10% DMSO    90% Corn Oil

      Solubility: ≥ 0.5 mg/mL (0.94 mM); 澄清溶液

      此方案可獲得 ≥ 0.5 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。

      以 1 mL 工作液為例，取 100 μL 5.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

    以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

    • 方案 一

      請(qǐng)依序添加每種溶劑： 50% PEG300    50% Saline

      Solubility: 4.17 mg/mL (7.88 mM); 懸濁液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.94%

    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.8885 mL 9.4425 mL 18.8850 mL 47.2126 mL
    5 mM 0.3777 mL 1.8885 mL 3.7770 mL 9.4425 mL
    10 mM 0.1889 mL 0.9443 mL 1.8885 mL 4.7213 mL
    15 mM 0.1259 mL 0.6295 mL 1.2590 mL 3.1475 mL
    20 mM 0.0944 mL 0.4721 mL 0.9443 mL 2.3606 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Nilotinib
    目錄號(hào)：
    HY-10159
    需求量：